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Abstract 
Gastrointestinal Stromal Tumor (GIST) is the most common mesenchymal tumor of the 
digestive tract.  GISTs develop with relatively high incidence in patients with Neurofibro-
matosis-1 syndrome (NF1).  Mutational activation of KIT or PDGFRA is believed to be a 
driving force in the pathogenesis of familial and sporadic GISTs.  Unlike those tumors, 
NF1-associated GISTs do not have KIT or PGDFRA mutations.  Similarly, no mutational ac-
tivation of KIT or PDGFRA has been identified in pediatric GISTs and in GISTs associated with 
Carney Triad and Carney-Stratakis Syndrome.  KIT and PDGFRA-wild type tumors are ex-
pected to have lesser response to imatinib treatment.  Recently, Carney Triad and Car-
ney-Stratakis Syndrome -associated GISTs and pediatric GISTs have been shown to have a 
loss of expression of succinate dehydrogenase subunit B (SDHB), a Krebs cycle/electron 
transport chain interface protein. It was proposed that GISTs can be divided into SDHB- 
positive (type 1), and SDHB-negative (type 2) tumors because of similarities in clinical features 
and response to imatinib treatment.  In this study, SDHB expression was examined im-
munohistochemically in 22 well-characterized NF1-associated GISTs. All analyzed tumors 
expressed SDHB. Based on SDHB-expression status, NF1-associated GISTs belong to type 1 
category; however, similarly to SDHB type 2 tumors, they do not respond well to imatinib 
treatment. Therefore, a simple categorization of GISTs into SDHB-positive and-negative 
seems to be incomplete. A classification based on both SDHB expression status and KIT and 
PDGFRA  mutation  status  characterize  GISTs  more  accurately  and  allow  subdivision  of 
SDHB-positive tumors into different clinico-genetic categories. 
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Introduction 
Neurofibromatosis-1 (NF1), also known as von 
Recklinghausen  disease,  is  an  inherited,  autosomal 
dominant  disease  phenotypically  characterized  by 
multiple café au lait spots, Lisch nodules, freckling, 
and development of neurofibromas, and in some cas-
es, their malignant derivatives [1]. Also, gastrointes-
tinal stromal tumors (GISTs) arise in NF1 patients 150 
times more frequently than in the general population 
[2].  With an estimated birth incidence  of 1:3000 in 
Western countries, NF1 is the most commonly inher-
ited disease [1]. It was postulated that NF1 is caused 
by a loss-of-function of tumor suppressor gene lead-Journal of Cancer 2011, 2 
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ing to the inactivation of neurofibromin that regulates 
cell proliferation and cell differentiation through in-
hibitory  regulation  of  the  ras  oncogene,  a  GTPase 
[3-7]. 
 Gastrointestinal  stromal  tumor  (GIST)  is  the 
most common mesenchymal neoplasm of the gastro-
intestinal tract. GISTs are believed to originate from 
the interstitial cells of Cajal, pacemaker cells that reg-
ulate  peristalsis  in  the  digestive  tract  [8].  An  onco-
genic (mutational) activation of KIT or PDGFRA ty-
rosine kinases has been identified in a great majority 
of  GISTs  [9].  However,    no  GIST-specific  KIT  or 
PDGFRA  mutations  were  identified  in  GIST  associ-
ated with NF1, Carney Triad (CT), Carney-Stratakis 
Syndrome  (CSS),  in  pediatric  GISTs,  or  in  a  small 
subset  (<10%)  of  sporadic  adult  GISTs  [10-14].  Mo-
lecular  mechanisms  underlying  the  development  of 
KIT/PDGFRA-wild  type  (WT)  GISTs  are  not  well 
understood.   
 Recently,  GISTs  associated  with  CT  (triad  of 
gastric  GIST,  pulmonary  chondroma,  and  ex-
tra-adrenal paraganglioma) and CSS (hereditary GIST 
paraganglioma syndrome) have been shown to have a 
loss  of  succinate  dehydrogenase  subunit  B  (SDHB) 
expression [15, 16]. SDHB, a mitochondrial protein, is 
one of the ubiquitously expressed proteins function-
ing  at  the  interface  of  tricarboxylic  acid  cycle  and 
electron  transport  chain.  It  is  believed  that  loss  of 
SDHB expression leads to a tumorigennic mechanism 
involving the stabilization of Hypoxia Inducing Fac-
tors  (HIF),  which  in  turn  upregulates  genes  that 
promote adaptation of cells in low-oxygen environ-
ments  by  inducing  angiogenesis  and  glycolysis 
[17-20].  
 Data  on  SDHB  expression  in  NF1-associated 
GISTs  are  limited  and  only  three  cases  were  tested 
and turned to be SDHB- positive [15]. The aim of this 
study was to evaluate SDHB expression in a signifi-
cant number of NF1-associated GISTs and test a hy-
pothesis that a lack of SDHB expression, unlike in CT- 
and CSS-associated tumors and pediatric GISTs, is not 
involved in pathogenesis of NF1-associated GISTs.  
Materials and Methods 
 A total of 23 NF1-associated GISTs, from years 
1970-1999, were obtained from the Armed Forces In-
stitute of Pathology (AFIP) tissue repository. 
 Immunostaining  was  performed  with  Leica 
Bond-Max  automatic  immunostainer  (Leica,  Ban-
nockburn, IL) using a commercially available SDHB 
mouse monoclonal antibody 21A11 (Abcam ab14714, 
Cambridge,  MA).  Heat  induced  epitope  retrieval 
(high  pH,  EDTA-based  buffer,  pH  9.0,  Leica 
Bond-Max) was applied for 25 minutes.  The primary 
antibody was incubated for 30 minutes at room tem-
perature.  Leica Bond-Max avidin-biotin free polymer 
system  was  used  in  the  detection according  to  the 
recommended  procedure.   Diaminobenzidine  was 
used  as  the  chromogen,  following  the  blocking  of 
endogenous peroxidase with 3% hydrogen peroxide 
diluted  in  phosphate  buffer.  Immunostained  slides 
were counterstained with hematoxylin.  Only stains 
with positive internal controls (granular cytoplasmic 
staining  in  vascular  endothelia  and  pericytes)  were 
considered  valid.  One  case  with  unsuccesful  im-
munostaining  (internal  control  negative)  was  re-
moved from the study. 
Results 
 All twenty two NF1-associated GISTs exhibited 
granular, cytoplasmic staining for SDHB (Fig. 1). In 
the analyzed cohort, there were 8 (36.4%) male and 14 
(63.6%) female patients. Median age at tumor diagno-
sis was 41 years (mean, 46 years). Twenty one tumors 
were located in the small intestine and one in colon. 
Tumor  sizes  varied  from  0.9  to  10  cm  (median,  3.5 
cm), and 15 patients presented with multiple tumors. 
Most  of  these  GISTs  had  mitotic  counts  <5  per  50 
HPFs, and only two tumors contained more than 5 
mitoses per 50 HPFs. KIT and DOG 1/Anoctamin-1 
were expressed in all tumors. GIST-specific KIT exon 
9, 11, 13, and 17, and PDGFRA exon 12, 14, and 18 
mutations were not found as previously reported [11].  
Discussion 
 In this study, we demonstrate consistent SDHB 
expression  in  neurofibromatosis  1  (NF1)-associated 
GISTs.  Clinicopathologic features of these GISTs in-
clude  patient  female  predominance,  small  intestinal 
location,  common  multiplicity,  KIT  and  DOG  1  ex-
pression, and lack of GIST-specific KIT and PDGFRA 
mutations,  as  previously  reported  [10,  11].  Lack  of 
GIST-specific  KIT  and  PDGFRA  mutations  has  also 
been reported in pediatric GISTs, Carney triad (CT) 
and  Carney-Stratakis  (CS)  syndrome-associated 
GISTs, and in a small subset of adult GISTs [10-14]. 
 Lack of SDHB expression has been reported in 
Carney  triad  (CT)  and  Carney-Stratakis  (CS)  syn-
drome-associated GISTs and more recently in pediat-
ric  and  adult  sporadic  GISTs  showing  morphologic 
and clinical features similar to CT- and CS-GISTs. It 
has been proposed that based on SDHB expression, 
GISTs  could  be  divided  into  2  distinctive  subtypes: 
SDHB- positive (type 1) and SDHB-negative (type 2) 
tumors [15]. Type 1 GISTs can occur in adults any-
where  in  the  gastrointestinal  tract,  have  equal  sex 
distribution,  generally  have  KIT  or  PDGFRA  muta-
tions, and, in majority, respond to imatinib treatment.  Journal of Cancer 2011, 2 
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Type 2 GISTs occur in childhood or young adulthood 
nearly  exclusively  in  the  stomach,  show  a  striking 
predilection  for  the  female  sex  and  epitheliod  mor-
phology. These tumors lack KIT or PDGFRA muta-
tions and show a limited response to imatinb inhibi-
tion [14].  
Based  on  SDHB-expression  status, 
NF1-associated  GISTs  belong  to  type  1  category. 
However, they differ from type 1 GIST characteristics 
by  restriction  of  occurrence  to  intestines,  common 
tumor  multiplicity,  female  predominance,  and  con-
sistent lack of GIST-specific KIT and PDGRA muta-
tions.  Similar  to  SDHB  type  2  tumors,  they  do  not 
respond well to imatinib treatment [21-23]. Therefore, 
clinicopathologically NF1-associated GISTs deserve a 
separation from other type 1 (SDHB-positive) GISTs.  
 Although imatinib mesylate, KIT and PDGFRA 
tyrosine  kinase  inhibitor  was  successfully  used  for 
treatment of advanced and disseminated GISTs [24], 
such a treatment is ineffective or minimally effective 
in  KIT/PDGFRA-wild  type  GISTs,  as  well  as  those 
with certain mutations, such as PDGFRA Asp842Val 
substitution [25]. Thus, genotyping of GISTs is con-
sidered  a  standard  clinical  test  in  all  disseminated 
GISTs and tumors with a substantial risk of develop-
ing metastatic disease.  
 In  conclusion,  NF1-associated  GISTs  express 
SDHB, similar to a majority of adult GISTs.  In view of 
different KIT/PDGFRA mutation status and prospect 
to targeted treatment, simple categorization of GISTs 
into type 1 and type 2 based on SDHB expression is 
inadequate. A classification based on both SDHB ex-
pression status and other clinicopatholopgic factors: 
KIT/PDGFRA  mutation  and  NF1  syndrome  status 
characterize GISTs more accurately allowing subdivi-
sion of SDHB-positive tumors into different categories 
based on these clinicopathologic factors (Table 1). 
 
 
 
 
   
Figure 1: A representative of Nf-1 GISTs of (a) 67 year old male, (b) 36 year old female, (c) 25 year old male, and (d) 60 year 
old male. A majority of Nf-1 associated GISTs exhibited positive, granular, cytoplasm staining for SDHB in gastrointestinal 
stromal tumors. All positively stained cells show granular cytoplasm (mitochondrial) staining pattern. 
 
 
 
   Journal of Cancer 2011, 2 
 
http://www.jcancer.org 
93 
Table 1. Classification of GISTs based on SDHB expression and KIT or PDGFRA mutation status.  
SDHB status  KIT/PDGFRA mutation   Clinical features  Sensitivity to imatinib 
SDHB-positive  KIT exon 9, 11, 13, and 17; 
PDGFRA exon 12, 14, and 18 
 
Sporadic or familial tumors (adult type)  Generally high, but varies (lower for KIT exon 
9  mutants  and  poor  response  for  the  most 
common PDGFRA exon 18 mutant (D842V) 
KIT/PDGFRA-WT 
 
Sporadic  
(non-syndromic) 
Low 
Neurofibromatosis-1 Syndrome   Low 
SDHB-negative  KIT/PDGFRA-WT  Carney Triad   Low 
Carney-Stratakis Syndrome   Low 
Sporadic tumors (pediatric type)  Low 
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